Clinical trials: Cancer of the Esophagus
Esophageal Cancer
Thoraco-laparoscopic Partial Esophagogastrectomy for Management of Esophageal Cancer
Thoraco-laparoscopic partial esophagogastrectomy has emerged as a promising minimally invasive alternative, combining thoracoscopy and laparoscopy to reduce the trauma associated with open surgery.Early and intermediate-term…
- Trial name
- NCT06879483
- Testing
- Thoraco-laparoscopic partial esophagogastrectomy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer…
- Trial name
- NCT05163483
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Ruihua Xu
Esophageal Squamous Cell Carcinoma
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma.
- Trial name
- NCT07700667
- Testing
- SKB500, Tislelizumab, Cisplatin
- Where
- 24 sites in China
- Volunteers
- 120 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Esophageal Cancer, Esophagus Cancer
Retrospective Review of Esophageal Cancer at MSKCC
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin…
- Trial name
- NCT05706558
- Testing
- Esophagectomy
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HNSCC, NSCLC
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic stages.
- Conditions
- HNSCC, NSCLC, Esophageal Cancer, Urothelial Carcinoma
- Trial name
- ST-ICI02 (NCT04892849)
- Testing
- Conventional Therapy acc. to prevailing clincal approved schemes
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Esophageal Cancer
Outside the Cage (OTC) Robotic Esophagectomy
The goal of this clinical trial is to evaluate the feasibility and safety of a novel non-intercostal robotic approach for minimally invasive esophagectomy (OTC MIE) in the treatment of esophageal cancer.
- Trial name
- NCT06735638
- Testing
- OTC MIE Esophagectomy
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Esophageal Cancer
A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC
The purpose of this study is to assess efficacy and safety of patients who receive camrelizumab as consolidation therapy after radical concurrent chemoradiotherapy in locally advanced ESCC.
- Trial name
- ESCC (NCT04286958)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
The purpose of this study is to explore the efficacy and safety of Toripalimab injection (JS001) given before and after concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04084158
- Testing
- Toripalimab injection (JS001), Paclitaxel, Albumin-Bound, Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021320
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fox Chase Cancer Center
Esophageal Squamous Cell Carcinoma, Positive Circumferential Resection Margin
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin
The purpose of this study is to determine the efficacy of adjuvant radiotherapy for esophageal squamous cell carcinoma with positive circumstantial resection margin.
- Trial name
- NCT03273647
- Testing
- radiation
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fudan University
Barrett's Esophagus, Esophageal Adenocarcinoma
Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue
This is a laboratory-based, exploratory study using tissue obtained from our clinical practice. The purpose of this study is to confirm our ability to characterize miR expression in various tissues (proximal and distal esophagus…
- Trial name
- NCT00909350
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Esophageal Squamous Cell Carcinoma
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell…
- Trial name
- HCHTOG2603 (NCT07629817)
- Testing
- Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy, Radiation with Concurrent Chemotherapy, Radical Esophagectomy
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer
Fluorescence Endoscopy of Esophageal Carcinoma
For locally advanced esophageal cancer (EC), neoadjuvant chemoradiotherapy (nCRT) for 5 weeks followed by esophagectomy and lymphadenectomy, if necessary, is standard of care.
- Trial name
- ORCA (NCT03558724)
- Testing
- Bevacizumab-IRDye800CW, Molecular Fluorescence Endoscopy platform
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- University Medical Center Groningen
Acute Kidney Injury, Postoperative Complications
Incidence, Risk Factors and Consequences of Acute Kidney Injury in Patients Undergoing Esophageal Cancer Surgery
Esophagectomy serves as an exemplar of major operative trauma, with well-known risk of pulmonary, cardiac, anastomotic, and septic complications and the presence of postoperative complications after esophagectomies for cancer is…
- Trial name
- NCT04773080
- Where
- Italy
- Volunteers
- 254 people
- Sponsor
- Azienda Ospedaliera di Padova
Esophageal Cancer, Cancer of the Esophagus
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease.
- Conditions
- Esophageal Cancer, Cancer of the Esophagus, Esophagus Cancer, Esophageal Neoplasm
- Trial name
- NCT00318903
- Testing
- Irinotecan (drug), Taxotere (drug), Radiotherapy (procedure)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Esophageal Cancer, Lung Cancer
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma
Phase I trial to study the effectiveness of topotecan and radiation therapy in treating patients who have solid tumors or lymphoma.
- Conditions
- Esophageal Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT00002625
- Testing
- topotecan hydrochloride, low-LET electron therapy, low-LET photon therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Esophagectomy
Shanghai Clinical Cohort - Esophageal Cancer
A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.
- Trial name
- NCT07312526
- Testing
- esophagectomy
- Where
- China
- Volunteers
- 2,116 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT assessment to change the following chemoradiotherapy regiment for locally…
- Trial name
- NCT06420908
- Testing
- Adebrelimab+TP/FP+ radiation therapy, Adebrelimab+FP/TP+ radiation therapy
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
NCI UNC Project ESCC
Background: Esophageal cancer is a common cause of cancer deaths. Most cases of this cancer are esophageal squamous cell carcinoma (ESCC). Many of these cases come from two parts of the world with high-risk.
- Trial name
- NCT03206125
- Where
- 2 sites in Malawi
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Stomach Neoplasms, Esophageal Neoplasms
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer.
- Trial name
- FOLFIRINOX (NCT01928290)
- Testing
- Irinotecan, Trastuzumab, Oxaliplatin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.